Why the study?
Does anti-Mac1 monoclonal antibody prevent EMCV-induced diabetes and myocarditis in DBA/2 mice?
Does anti-Mac1 monoclonal antibody prevent EMCV-induced diabetes and myocarditis in DBA/2 mice?
Depletion of Mac1-positive macrophages protects against EMCV-induced myocarditis and diabetes in a mouse model, suggesting a role for these cells in viral replication and disease pathogenesis.
Preclinical Mac1 blockade protects against EMCV disease in mice; leaves open macrophage-targeted therapy for human viral myocarditis or diabetes.
DBA/2 mice treated with anti-Mac1 monoclonal antibody (MAb) failed to develop encephalomyocarditis virus (EMCV)-induced diabetes and myocarditis. Virus concentrations and the number of viral RNA-positive cells in the pancreas and heart were significantly reduced in mice treated with anti-Mac1 MAb. Mac1-positive macrophages seem to be involved in EMCV-induced disease and to affect the replication of EMCV in target organs.
No takes yet. Share an insight, caveat, or question.
Hirasawa et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: